Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
1
20%
Ph phase_3
3
60%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Recruiting2
Completed1
Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed120%
not_yet_recruiting120%
recruiting240%
enrolling_by_invitation120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

NCT06564818
recruitingphase_3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397
enrolling_by_invitationphase_3

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

NCT06605105
not_yet_recruitingphase_2

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

NCT06820723
completedphase_1

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783

Clinical Trials (5)

Showing 5 of 5 trials
NCT06564818Phase 3

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Recruiting
NCT06793397Phase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Recruiting
NCT06605105Phase 3

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

Enrolling By Invitation
NCT06820723Phase 2

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

Not Yet Recruiting
NCT05385783Phase 1

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5